ArticleApplied biochemistry and biotechnology2026
DIP2B as a Prognostic Biomarker and Immunotherapy Target: Insights from Pan-Cancer Analysis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The protein encoded by the Disco-interacting protein 2 homolog B (DIP2B) gene contains DNA methyltransferase and adenosine monophosphate (AMP) binding sites. Although DIP2B has been implicated in tumorigenesis, its diagnostic and prognostic significance across various cancers remains unclear. A comprehensive data analysis was performed using multiple bioinformatics platforms and tools, including the TCGA and GTEx databases, the R programming language, STRING, Cytoscape, TISIDB, cBioPortal, GSCALite, HPA, NetworkAnalyst, and CancerSEA. DIP2B expression was elevated in multiple cancer types, with variations observed across different immune and molecular subtypes. DIP2B was implicated in numerous cancer-related signaling pathways and showed enhanced diagnostic and prognostic significance across malignancies. Transcription factor analysis identified specificity protein 1 (SP1), specificity protein 3 (SP3), and histone deacetylase 1 (HDAC1) as potential regulators of DIP2B expression.In addition, a positive correlation was found between DIP2B and central memory CD8 T cells in cancers, suggesting a potential role in immune modulation. DIP2B shows promise as a prognostic biomarker and may represent anovel target for immunotherapy.
Indexed as
Identifiers
41484749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.